A new stem cell approach opens the door to a potential cure for Type 1 diabetes. A groundbreaking preclinical study shows that a chemotherapy-free, non-myeloablative conditioning regimen can establish durable mixed hematopoietic chimerism, restore immune tolerance, and completely reverse autoimmune Type 1 diabetes in mouse models. This promising result could lead to safer transplantation-based strategies for correcting autoimmunity in humans, avoiding the toxicity associated with traditional bone marrow conditioning.
Mixed Hematopoietic Chimerism as a Route to Immune Tolerance
For years, mixed hematopoietic chimerism has been seen as a way to promote tolerance to donor organs and correct autoimmune diseases. Yet its clinical use has been hampered by the harsh conditioning regimens needed for engraftment. To overcome this hurdle, researchers devised a chemotherapy-free, non-myeloablative protocol that combines an anti-c-Kit monoclonal antibody, T-cell-depleting antibodies, JAK1/2 inhibition, and low-dose total body irradiation.
In prediabetic NOD mice, this regimen successfully enabled engraftment of MHC-mismatched B6 hematopoietic cells, establishing stable mixed chimerism. Notably, diabetes did not develop in any treated animals, indicating complete protection against autoimmune destruction of pancreatic islets.
Reversing Established Diabetes and Achieving Allograft Tolerance
When the same conditioning approach was used in mice with established diabetes, it was paired with B6 hematopoietic cell transplantation and islet transplantation. All chimeric mice showed durable normalization of blood glucose without ongoing immunosuppression. There were no cases of graft-versus-host disease, and immune competence remained intact—as evidenced by normal blood counts and the ability to reject third-party allogeneic islets.
Mechanistic investigations highlighted central thymic deletion of autoreactive T cells together with peripheral regulatory processes, confirming the restoration of immune tolerance. Adoptive transfer experiments further demonstrated that autoimmune activity had been genuinely corrected rather than merely suppressed.
Toward a Cure for Type 1 Diabetes
Collectively, these findings imply that non-toxic, mixed hematopoietic chimerism could become a transformative therapeutic path for autoimmune Type 1 diabetes, enabling a durable immune reset, islet allograft tolerance, and even reversal of established disease. While translating these results to humans will require careful evaluation, the study provides compelling evidence that effective immune reprogramming may be achievable without the risks associated with conventional conditioning.
Reference
Bhagchandani P, et al. Curing autoimmune diabetes in mice with islet and hematopoietic cell transplantation after CD117 antibody-based conditioning. J Clin Invest. 2025; DOI:10.1172/JCI190034.
Author
Each article is available under the Creative Commons Attribution-Non Commercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/).
